Assenagon Asset Management S.A. Sells 100,518 Shares of CareDx, Inc (NASDAQ:CDNA)

Assenagon Asset Management S.A. lessened its position in CareDx, Inc (NASDAQ:CDNA - Free Report) by 60.4% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 65,787 shares of the company's stock after selling 100,518 shares during the period. Assenagon Asset Management S.A. owned 0.13% of CareDx worth $2,054,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in CDNA. Allspring Global Investments Holdings LLC raised its stake in CareDx by 868.6% in the third quarter. Allspring Global Investments Holdings LLC now owns 204,987 shares of the company's stock worth $6,401,000 after buying an additional 183,823 shares in the last quarter. Harbour Capital Advisors LLC purchased a new position in shares of CareDx in the 3rd quarter valued at approximately $373,000. nVerses Capital LLC boosted its position in shares of CareDx by 175.0% during the third quarter. nVerses Capital LLC now owns 3,300 shares of the company's stock valued at $103,000 after purchasing an additional 2,100 shares in the last quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd purchased a new stake in CareDx in the third quarter worth $206,000. Finally, Creative Planning bought a new position in CareDx in the third quarter worth $204,000.

Analyst Ratings Changes

A number of research firms have recently weighed in on CDNA. The Goldman Sachs Group upped their target price on shares of CareDx from $26.00 to $35.00 and gave the stock a "buy" rating in a research report on Wednesday, October 16th. Craig Hallum lifted their target price on shares of CareDx from $22.00 to $32.00 and gave the company a "buy" rating in a report on Thursday, August 1st. StockNews.com upgraded CareDx from a "hold" rating to a "buy" rating in a research note on Thursday, October 17th. HC Wainwright reiterated a "neutral" rating on shares of CareDx in a research note on Tuesday, October 22nd. Finally, BTIG Research raised CareDx from a "neutral" rating to a "buy" rating and set a $40.00 target price on the stock in a report on Monday, August 19th. One research analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the stock. According to MarketBeat, CareDx presently has an average rating of "Moderate Buy" and an average price target of $30.60.

CareDx Stock Performance

Shares of CDNA stock traded up $0.51 during mid-day trading on Friday, hitting $22.64. The company's stock had a trading volume of 721,349 shares, compared to its average volume of 898,501. CareDx, Inc has a 52-week low of $5.89 and a 52-week high of $34.84. The business has a 50-day moving average price of $28.23 and a 200 day moving average price of $20.47. The stock has a market cap of $1.19 billion, a price-to-earnings ratio of -7.40 and a beta of 1.77.

CareDx (NASDAQ:CDNA - Get Free Report) last posted its quarterly earnings results on Wednesday, July 31st. The company reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.37. CareDx had a negative return on equity of 53.65% and a negative net margin of 53.73%. The firm had revenue of $92.27 million during the quarter, compared to analysts' expectations of $67.20 million. Equities research analysts predict that CareDx, Inc will post -0.83 EPS for the current fiscal year.

Insider Transactions at CareDx

In related news, insider Alexander L. Johnson sold 21,557 shares of the company's stock in a transaction on Wednesday, August 21st. The stock was sold at an average price of $32.58, for a total transaction of $702,327.06. Following the completion of the sale, the insider now owns 284,983 shares in the company, valued at approximately $9,284,746.14. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other CareDx news, insider Alexander L. Johnson sold 34,231 shares of the company's stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $33.55, for a total value of $1,148,450.05. Following the completion of the sale, the insider now owns 284,983 shares in the company, valued at $9,561,179.65. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Alexander L. Johnson sold 21,557 shares of the company's stock in a transaction dated Wednesday, August 21st. The stock was sold at an average price of $32.58, for a total value of $702,327.06. Following the completion of the sale, the insider now owns 284,983 shares of the company's stock, valued at approximately $9,284,746.14. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 91,340 shares of company stock worth $3,025,415 over the last quarter. 4.90% of the stock is currently owned by insiders.

CareDx Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.